These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15950208)

  • 1. Self-peptide/MHC and TCR antagonism: physiological role and therapeutic potential.
    Vukmanović S; Santori FR
    Cell Immunol; 2005 Feb; 233(2):75-84. PubMed ID: 15950208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying the strength of ligand antagonism in TCR triggering.
    Van Den Berg HA; Burroughs NJ; Rand DA
    Bull Math Biol; 2002 Jul; 64(4):781-808. PubMed ID: 12216421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand.
    Choudhuri K; Wiseman D; Brown MH; Gould K; van der Merwe PA
    Nature; 2005 Jul; 436(7050):578-82. PubMed ID: 16049493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen analogs as tools to study T-cell activation function and activation.
    Sette A; Alexander J; Snoke K; Grey HM
    Semin Immunol; 1996 Apr; 8(2):103-8. PubMed ID: 8920244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strength of TCR-peptide/MHC interactions and in vivo T cell responses.
    Corse E; Gottschalk RA; Allison JP
    J Immunol; 2011 May; 186(9):5039-45. PubMed ID: 21505216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specificity of T-cell alloreactivity.
    Felix NJ; Allen PM
    Nat Rev Immunol; 2007 Dec; 7(12):942-53. PubMed ID: 18007679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen analogs/MHC complexes as specific T cell receptor antagonists.
    Sette A; Alexander J; Ruppert J; Snoke K; Franco A; Ishioka G; Grey HM
    Annu Rev Immunol; 1994; 12():413-31. PubMed ID: 8011286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural immunology and crystallography help immunologists see the immune system in action: how T and NK cells touch their ligands.
    Chen Y; Shi Y; Cheng H; An YQ; Gao GF
    IUBMB Life; 2009 Jun; 61(6):579-90. PubMed ID: 19472182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What guides MHC-restricted TCR recognition?
    Mazza C; Malissen B
    Semin Immunol; 2007 Aug; 19(4):225-35. PubMed ID: 17521918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct orientation of the alloreactive monoclonal CD8 T cell activation program by three different peptide/MHC complexes.
    Auphan-Anezin N; Mazza C; Guimezanes A; Barrett-Wilt GA; Montero-Julian F; Roussel A; Hunt DF; Malissen B; Schmitt-Verhulst AM
    Eur J Immunol; 2006 Jul; 36(7):1856-66. PubMed ID: 16761314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of CD8 and TCR binding to Class I MHC ligands following T cell activation.
    Kao C; Daniels MA; Jameson SC
    Int Immunol; 2005 Dec; 17(12):1607-17. PubMed ID: 16263755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural alterations in peptide-MHC recognition by self-reactive T cell receptors.
    Wucherpfennig KW; Call MJ; Deng L; Mariuzza R
    Curr Opin Immunol; 2009 Dec; 21(6):590-5. PubMed ID: 19699075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation.
    Denkberg G; Reiter Y
    Autoimmun Rev; 2006 Apr; 5(4):252-7. PubMed ID: 16697965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell allorecognition and MHC restriction--A case of Jekyll and Hyde?
    Archbold JK; Ely LK; Kjer-Nielsen L; Burrows SR; Rossjohn J; McCluskey J; Macdonald WA
    Mol Immunol; 2008 Feb; 45(3):583-98. PubMed ID: 17869342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-canonical anchor motif peptides bound to MHC class I induce cellular responses.
    Lazoura E; Lodding J; Farrugia W; Day S; Ramsland PA; Apostolopoulos V
    Mol Immunol; 2009 Mar; 46(6):1171-8. PubMed ID: 19118903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multispecific responses by T cells expanded by endogenous self-peptide/MHC complexes.
    Cai G; Hafler DA
    Eur J Immunol; 2007 Mar; 37(3):602-12. PubMed ID: 17304631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting costimulatory pathways for tumor immunotherapy.
    Ward RC; Kaufman HL
    Int Rev Immunol; 2007; 26(3-4):161-96. PubMed ID: 17558743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypothesis: TCR signal transduction--A novel tri-modular signaling system.
    Amon MA; Manolios N
    Mol Immunol; 2008 Feb; 45(4):876-80. PubMed ID: 17915329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease.
    Kohm AP; Turley DM; Miller SD
    Int Rev Immunol; 2005; 24(5-6):361-92. PubMed ID: 16318987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Degenerate T-cell receptor recognition, autoreactive cells, and the autoimmune response in multiple sclerosis.
    Markovic-Plese S
    Neuroscientist; 2009 Jun; 15(3):225-31. PubMed ID: 19297658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.